Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonicotinic Acid SCHEMBL3705303 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25271513 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL11323095 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273147 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25269382 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273296 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25270921 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25261209 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL5858849 | 0.95 | CA2 (0.56) | NAPRTALDH1A1CA2CA4MEN1 | |
| Isonicotinic Acid SCHEMBL25273196 | 0.95 | NAPRT (0.56) | NAPRTALDH1A1CA2CA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995021030-A1 | EFFICIENT CHEMISTRY FOR SELECTIVE MODIFICATION AND METALLIZATION OF SUBSTRATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1995-08-10 | — | — | WO | claimed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060128608-A1 | Novel chemical compounds and their use | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2006-06-15 | — | — | US | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| US-5648201-A | Efficient chemistry for selective modification and metallization of substrates | THE UNITED SATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1995021030-A1 | EFFICIENT CHEMISTRY FOR SELECTIVE MODIFICATION AND METALLIZATION OF SUBSTRATES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128608-A1 | Novel chemical compounds and their use | PGLS, ABCG2, UGCG | NAPRT 83/4885ALDH1A1 798/4885CA2 2364/4885 |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | NAPRT 2025/4885ALDH1A1 591/4885CA2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.